Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain
The analysis shows that dapagliflozin, as add-on therapy to SoC, would be a cost-effective option compared to SoC for the treatment of adult patients with symptomatic chronic HF in Spain at a WTP of €25,000/QALY.
Authors
- Domingo A. Pascual‐Figal (ORCID: https://orcid.org/0000-0002-4993-9540)
- Margarita Capel (ORCID: https://orcid.org/0000-0001-9431-6302)
- Elisenda Pomares Mallol
- Christian Caudron
- Josep Maria Guiu-Segura
- Carlos Escobar (ORCID: https://orcid.org/0009-0003-7350-3098)
Institutions
- Hospital Universitario La Paz (ES)
- Spanish National Centre for Cardiovascular Research (ES)
- AstraZeneca (Spain) (ES)
- Hospital Universitario Virgen de la Arrixaca (ES)
- Consortium for Health and Social Catalonia (ES)
- Universidad de Murcia (ES)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1186/s12913-025-13089-7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- AstraZeneca España